OBJECTIVE: To develop and characterize a new head and neck cancer animal model.
STUDY DESIGN: A human head and neck squamous cell carcinoma (HNSCC) xenograft model in nude rats was established via subcutaneous inoculation of a human-origin HNSCC cell line, SCC-4. The tumor was evaluated for growth characteristics, pathologic features by hematoxylin-eosin (HE) staining, and immunohistochemistry of epidermal growth factor receptor (EGFR). 2-[18F] fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET) imaging characteristics were studied too.
RESULTS: A new HNSCC animal model was successfully established. Tumor sizes reached about 1 cm3 on day 15 after tumor cell inoculation. HE staining pathology has confirmed that this tumor is a typical SCC. EGFR immunohistochemistry demonstrated this tumor model to be strongly EGFR positive. 18F-FDG PET study has shown that 18F-FDG accumulated in tumors.
CONCLUSIONS: This study has demonstrated that this tumor model is an appropriate HNSCC tumor model for animal studies on HNSCC.
Get full access to this article
View all access options for this article.
References
1.
PrasadMLHuvosAG.Pathology of head and neck tumors. In: ShahJP, editor. American Cancer Society atlas of clinical oncology: cancer of the head and neck. London: BC Decker; 2001. p. 19–55.
2.
HalfpennyWHainSFBiassoniL, et al. FDG--PET. A possible prognostic factor in head and neck cancer. Br J Cancer2002; 86: 512–6.
3.
KostakogluLGoldsmithSJ.PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med2004;45:56–68.
4.
NagatsukaHHibiKGunduzM, et al. Various immunostaining patterns of CD31, CD34 and endoglin and their relationship with lymph node metastasis in oral squamous cell carcinoma. J Oral Pathol2005;34:70–6.
5.
BaoAPhillipsWTGoinsB, et al. Potential use of drug-carried liposomes for cancer therapy via direct intratumoral injection. Intl J Pharm2006;316:162–9.
6.
TomaycoMMReynoldsCP.Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol1989;24:148–54.
7.
SorensenGAPatelSHarmathC, et al. Comparison of diameter and perimeter methods for tumor volume calculation. J Clin Oncol2001;19:551–7.
8.
ModjtahediHEcclesSBoxG, et al. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor--receptor interaction. Br J Cancer1993;67:254–61.
9.
MendelsohnJBaselgaJ.Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol2003;21:2787–99.
10.
LynchTJBellDWSordellaR, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non--small-cell lung cancer to gefitinib. N Engl J Med2004;350:2129–39.
11.
GuillermoPJJannePALeeJC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science2004;304:1497–1500.
12.
MillerFRHusseyDBeermanM, et al. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg2005;131:626–9.
13.
DearlingJLJFlynnAASutcliffe-GouldenJ, et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med2004;45:101–7.
14.
ObataAYoshimotoMKasamatsuS, et al. Intra-tumoral distribution of 64Cu-ATSM: A comparison study with FDG. Nucl Med Biol2003;30:529–34.
15.
WeberWA.Brown adipose tissue and nuclear medicine imaging. J Nucl Med2004;45:1101–3.
16.
JainRKBaxterLT.Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res1988;48:7022–32.
17.
HeldinC-HRubinKPietrasK, et al. High interstitial fluid pressure--an obstacle in cancer therapy. Nature Rev Cancer2004;4:806–13.
18.
FunkTSunMHasegawaBH.Radiation dose estimate in small animal SPECT and PET. Med Phys2004;31:2680–6.
